This Week Last Year in Medtech: April 2 – 8

Fractyl Wins FDA Nod for New Revita Pivotal Study

The Lexington, MA-based company said the study aims to examine the effect of Revita on improving glycemic control and preventing the need for insulin therapy.

Bioventus Sets Its Sights on CartiHeal

Bioventus said it has exercised its call option to acquire CartiHeal for about $315 million, with an additional approximately $135 million payable contingent upon the achievement of $100 million in trailing 12 month sales.

And Now There Are 2 Leadless Pacemakers

FDA approved Abbott's Aveir VR leadless pacemaker. Will Boston Scientific's Empower MPS be next?

Medtronic Data Revives Hope in Renal Denervation for Blood Pressure Reduction

Three reasons why Medtronic's three-year renal denervation data is a really big deal.

New GE Healthcare Partnership Could Advance Brain Imaging

A collaboration between GE Healthcare and Imeka could help researchers and clinicians quickly obtain highly localized views of white matter, which can yield valuable insights into the impact of central nervous system diseases and disorders.

Dexcom's Savvy Business Move into New Geographies

The Dexcom One will be available to diabetes patients in the UK in May. Here's what you should know about the new continuous glucose monitoring system.

Study Shows SonoCloud Ultrasound Technology Is Safe for Alzheimer’s Patients

The first results of a clinical trial show the safety and therapeutic potential of transient repeated blood-brain-barrier disruption in Alzheimer’s patients.

AI Software Detects Breast Cancer Metastases in Lymph Nodes

Paige now has CE-IVD and UKCA marks for a new AI medical device software designed to help pathologists detect if breast cancer has spread to lymph nodes.

One Ukraine Lab Kept Working Until the Gas Ran Out

Qiagen CEO shares story of one lab's undeterred commitment in Ukraine.

Senseonics Launches Eversense, but Is Dexcom’s G7 Far Behind?

Senseonics has a longer runway in the CGM market. However, Dexcom has been busy building out its offerings until it wins approval for G7.